환자가 신뢰하는 치료, 환자가 만족하는 결과
사회의 변화, 출산의 감소, 서구적 식습관과 생활습관의 변화로 자궁근종, 자궁선근증 환자가 늘어나고 있습니다.
자궁근종과 자궁선근증은 하혈, 월경과다, 골반통증, 생리통, 골반압박감, 빈뇨 등 다양한 증상을 일으키는 양성질환으로 악성의 빈도는 낮지만 건강과 일상생활에 큰 불편을 주는 질환입니다.
기존의 전통적인 치료로는 약물치료와 수술적치료가 있는데 약물치료는 수술을 지연시키고자 시행되는 일시적인 호르몬 치료이며, 수술적 치료는 전신마취를 통한 근종절제 수술이나 자궁적출 수술 등의 침습적인 치료가 자궁근종과 자궁선근증의 치료로 일반적으로 시행되어왔습니다.
자궁은 여성고유의 소중한 기관으로 심리적, 신체적으로 중요하기 때문에 대부분의 여성이 자궁을 보존하길 원하지만 현재까지의 대부분의 치료는 자궁을 희생하면서 치료해 왔습니다.
초음파유도 하이푸나이프 자궁근종 및 자궁선근증 치료는 일시적인 호르몬 치료보다는 근본적인 치료이며 전신마취와 침습적인 수술을 피하면서 자궁을 보존하고, 기존의 수술적 치료보다 임신과 출산에 더 안전하게 근종을 효과적으로 치료하는 새로은 치료법입니다.
자궁근종과 자궁선근증을 조기 검진을 통해 발견하시고 악화되기 전미리 하이푸 시술을 통해서 치료하시길 바랍니다.
소중한 여성의 자궁을
보호하기 위한 절대적 비수술 치료를
하이푸 치료 적응증 환자 선별
개인에 맞는 치료방법 권유
안전하고 효과적인 시술을 통한
자궁 건강 회복 및 임신
진화된 여성질환 하이푸 치료
OBJECTIVES: This study aimed to assess the therapeutic outcomes of patients with uterine fibroid or adenomyosis treated by ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation at Incheon Christian Hospital, Korea.
METHODS: This study included 618 patients, of which 272 suffered from uterine fibroid and 346 suffered from adenomyosis. Treatment was administrated using the Model Haifu JC Focused Ultrasound Tumor Therapeutic System (Chongqing Haifu Technology, Chongqing, China) under real-time ultrasound guidance. A follow-up was conducted on volume change as well as on symptom improvement using the Symptom Severity Score (SSS) and Uterine Fibroid Symptom and Quality of Life (UFS-QOL) after treatment.
RESULT: The uterine fibroid volume reduction rates (%) were 58.08%, 66.18%, and 77.59% at 3, 6, and 12 months after treatment, respectively. The SSS reduction rates (%) were 55.58%, 52.76%, and 50.39% by 3, 6, and 12 months, respectively. The UFS-QOL score increasing rates (%) were 42.66%, 43.50%, and 43.45% by 3, 6, and 12 months, respectively. The uterine volume reduction rates (%) for adenomyosis were 43.99%, 47.01%, and 53.98% by 3, 6, and 12 months, respectively. The SSS reduction rates (%) for adenomyosis were 55.61%, 52.38%, and 57.98% by 3, 6, and 12 months, respectively. The UFS-QOL score increasing rates (%) for adenomyosis UFS-QOL score were 80.06%, 69.39%, and 85.07% by 3, 6, and 12 months, respectively.
CONCLUSION: We conclude that USgHIFU treatment for uterine fibroid and adenomyosis is an effective non-invasive therapy via the assessment of fibroid volume reduction, symptom improvement, UFS-QOL score increase, and acceptable level of side effects. Although preliminary experience of HIFU is encouraging, well-designed prospective trials and more clinical experiences are needed to ascertain the efficacy and safety of this new treatment.
Effects of High-Intensity-Focused Ultrasound Treatment on Benign Uterine Tumor. (J Korean Med Sci. 2016 Aug;31(8):1279-83. doi: 10.3346/jkms.2016.31.8.1279. Epub 2016 Jun 7.)
In this study, the effects of high-intensity-focused ultrasound (HIFU) treatment on benign uterine tumor patients were examined. A total of 333 patients diagnosed with fibroids or adenomyosis using diagnostic sonography, treated with HIFU between February 4, 2010 and December 29, 2014 at a hospital in Korea, and followed up for three or six months were selected for this study. Their benign uterine tumor volume was measured, and the effects of HIFU treatment on the volume were analyzed according to age, disease, fertility, and treatment duration. The volume of benign tumors of the uterus changed by age in all age groups after conducting HIFU treatment for 3 and 6 months, respectively. The rate of decrease in individuals' in their twenties was the largest, at 64.9%. When the decreasing volume of benign tumors of the uterus was analyzed by type of disease, the treatment efficacy for adenomyosis was the best, with a decrease of 164.83 cm(3) after 6 months. Myoma had the fastest decreasing rate, at 68.5%.
When evaluated on the basis of fertility, the volume of benign tumors of the uterus continued to decrease until 6 months after completing all procedures. The volume has continued to decrease for 6 months after all procedures. This study showed that HIFU treatments for uterine fibroid and adenomyosis is an effective non-invasive therapy via reducing the benign uterine tumor volume.
Therefore, the HIFU method might replace other conventional treatment methods.
High-intensity focused ultrasound combined with hysteroscopic resection to treat retained placenta accreta. (Obstet Gynecol Sci. 2016 Sep;59(5):421-5. doi: 10.5468/ogs.2016.59.5.421. Epub 2016 Sep 13.)
We present a case of retained placenta accreta treated by high-intensity focused ultrasound (HIFU) ablation followed by hysteroscopic resection. The patient was diagnosed as submucosal myoma based on ultrasonography in local clinic. Pathologic examination of several pieces of tumor mass from the hysteroscopic procedure revealed necrotic chorionic villi with calcification. HIFU was performed using an ultrasound-guided HIFU tumor therapeutic system. The ultrasound machine had been used for real-time monitoring of the HIFU procedure. After HIFU treatment, no additional vaginal bleeding or complications were observed. A hysteroscopic resection was performed to remove ablated placental tissue 7 days later. No abnormal vaginal bleeding or discharge was seen after the procedure. The patient was stable postoperatively. We proposed HIFU and applied additional hysteroscopic resection for a safe and effective method for treating retained placenta accreta to prevent complications from the remaining placental tissue and to improve fertility options.
‘자궁근종과 자궁선근증 치료의 새로운 대안 : 초음파영상 유도하 고강도 초음파절제술’
Successful Pregnancy and Term Delivery Following Ultrasound-Guided High-Intensity Focused Ultrasound (USgHIFU) Surgery of adenomyosis and uterine leiomyoma: cases report
Ultrasound-guided High-Intensity Focused Ultrasound Treatment for Uterine Fibroid & Adenomyosis : A Single Center Experience
Ultrasound-guided High-Intensity Focused Ultrasound Treatment for Uterine Fibroid & Adenomyosis Successful Pregnancy with Term Delivery Following Ultrasound-Guided High-Intensity Focused Ultrasound (USgHIFU) Ablation
Changes in antimullerian hormone levels as a biomarker of ovarian reserve after ultrasound-guided high- intensity focused ultrasound treatment of adenomyosis and uterine fibroid